List is tentative, and subject to change at any time.
ProGel delivers meds for long-term local effect
Ensign Pharmaceutical (University of Nebraska Medical Center)
ProGel is a platform technology with a diverse spectrum of drug payloads, such as steroids, statins, antioxidants, opioids, chemotherapeutics, and hormones. Ensign Pharmaceutical’s initial product focuses on managing osteoarthritis pain, incorporating a potent steroid, dexamethasone, into the formulation.
Small molecule shows first-in-human MoA for salivary gland cancers
SuviCa (University of Colorado-Bolder)
SVC112 is a late-preclinical stage asset with potent single agent activity in genetically-defined models of salivary gland cancer, a neglected and orphan disease with no approved targeted or immunotherapy agents.
New approach has potential to cure pulmonary arterial hypertension
Drax Therapeutic Inc. (Indiana University)
Pulmonary arterial hypertension (PAH) affects 200, 000 people annually and there is no cure for this condition. Researchers at Indiana University and University of Illinois at Chicago, have identified a potential drug for curing PAH.
Validus Cellular Therapeutics (Colorado State University)
For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics, which are susceptible to resistance and are limited accessing infections.